Company news

Enanta Pharmaceuticals, Inc. news in 2022

Enanta Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Enanta Pharmaceuticals to Participate in Two Investor Conferences in November

November 21, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4: 30 p.m. ET

November 20, 2022

Enanta Pharmaceuticals to Host Conference Call on November 21 at 4: 30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022

November 13, 2022

Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

November 8, 2022

Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022

October 18, 2022

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

October 16, 2022

Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

October 2, 2022

Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium

September 28, 2022

Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium

September 21, 2022

New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022

September 6, 2022

Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

August 31, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4: 30 p.m. ET

August 7, 2022

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

August 7, 2022

Enanta Pharmaceuticals to Host Conference Call on August 8 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022

July 31, 2022

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

July 28, 2022

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer

June 20, 2022

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022

June 7, 2022

Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

June 1, 2022

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

May 17, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4: 30 p.m. ET

May 8, 2022

Enanta Pharmaceuticals to Host Conference Call on May 9 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022

May 1, 2022

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

March 28, 2022

Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

March 7, 2022

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

February 16, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4: 30 p.m. ET

February 7, 2022

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021

January 31, 2022

Calls in 2022